3CLogic and NewRocket Forge Strategic Partnership to Deliver Seamless Contact Center Solutions for Financial Services with ServiceNow
ROCKVILLE, Md. , May 1, 2025 /CNW/ -- 3CLogic, the leading AI-powered contact center platform purpose-built for ServiceNow®, today announced a strategic partnership with NewRocket, an Elite ServiceNow partner. Under the expanded agreement, NewRocket will serve as an official reseller of 3CLogic's AI-driven Contact Center solutions to be leveraged as part of its broader Bank of NewRocket offering focused on transforming the Financial Services industry.
The collaboration comes at a pivotal time, as ServiceNow continues to emphasize front-office innovation across the financial sector. Voice remains a crucial channel for customer engagement, with recent reports1 suggesting a continued increase in call volumes of which approximately 50% remain repetitive and transactional. Together, the partnership will enable financial institutions to deliver more cohesive, intelligent service experiences by seamlessly integrating voice into the ServiceNow platform to resolve common requests faster.
"As financial institutions strive to modernize their customer service strategies, contact centers continue to be a vital part of the equation," said NewRocket's CRO, Michael Carter . "With our deep experience in the ServiceNow ecosystem and dedicated offerings like Bank of NewRocket, we're excited to empower clients with enhanced voice capabilities that drive efficiency and elevate customer experiences."
As a ServiceNow-certified and Advanced Platform Build partner, 3CLogic's brings a host of advanced capabilities to ServiceNow, including Voice AI for self-service, real-time transcription, unified agent workspaces in ServiceNow, GenAI call summaries and AI-powered insights. These features empower financial organizations to reduce call volumes, break down data silos, and reduce daily operating costs—all while improving customer satisfaction.
The joint solution will support use cases that commonly drive high call volumes—such as password resets, address change requests, and credit fraud reporting—by automating responses and enhancing agent workflows. As an authorized global reseller, NewRocket will also streamline implementation and deployment, helping clients accelerate time-to-value and ensure long-term success with their contact center and voice strategies.
"We are excited to expand our relationship with NewRocket," states Guillaume Seynhaeve , SVP of Alliances. "Our partnership reinforces our shared commitment to helping financial institutions deliver smarter, more responsive customer service powered by the Now Platform."
3CLogic and NewRocket plan to showcase their combined capabilities at ServiceNow's upcoming annual conference, Knowledge25. For more information on 3CLogic's Voice AI and Contact Center solutions for ServiceNow or details about the partnership, please visit www.3clogic.com or contact NewRocket here.
About 3CLogic
3CLogic transforms customer and employee experiences with its patented and award-winning AI-powered cloud contact center solutions purpose-built to enhance today's leading CRM and Customer Service Management platforms. Globally available and leveraged by the world's leading brands, its offerings empower enterprise organizations with innovative capabilities, such as intelligent self-service, Generative AI, Conversational AI, agent automation & coaching, and AI-powered sentiment analytics — all designed to lower operational costs, maximize ROI , and deliver better, faster, and more personalized interactions for IT, employee, and customer service. For more information, please visit www.3clogic.com .
About NewRocket
NewRocket, a global, full-service Elite ServiceNow partner, helps top enterprise leaders solve their toughest business problems and navigate change with confidence. Our mission is to simplify the lives of global enterprise industry leaders by helping them go beyond workflows with ServiceNow. Our vision is to be the world's most trusted, go-to ServiceNow partner for global enterprise industry leaders. NewRocket has been awarded the "2024 L&D BEST Award", "2024 ServiceNow Employee Workflow Partner of the Year", "2023 ServiceNow Worldwide Customer Workflow Partner of the Year" and "2023 ServiceNow Creator Workflow Partner of the Year". We are #GoingBeyond. For more information, please visit www.newrocket.com.
1https://www.mckinsey.com/capabilities/operations/our-insights/the-contact-center-crossroads-finding-the-right-mix-of-humans-and-ai
SOURCE 3CLogic
G. Seynhaeve, [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY Français
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY ® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy. "This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia," said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. "These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need." New longer-term follow-up data presented from the CASGEVY trials In SCD, 43/45 (95.6%) evaluable patients (those with at least 16 months of follow-up) were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months (VF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 84.9%, 99.5%). The mean duration of VOC-free was 35.0 months (range 14.4 to 66.2 months). All evaluable patients (45/45 [100%]) achieved freedom from in-patient hospitalization for severe VOCs for at least 12 consecutive months (HF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 92.1%, 100%), with a mean hospitalization-free of 36.1 months (range 14.5 to 66.2 months). In TDT, 54/55 (98.2%) evaluable patients (those with at least 16 months of follow-up) achieved transfusion-independence for at least 12 consecutive months with a weighted average hemoglobin (Hb) of at least 9 g/dL (TI12) in CLIMB-111 and CLIMB-131 combined (95% CI: 90.3%, 100%). The mean duration of transfusion independence was 40.5 months (range 13.6 to 70.8 months). The one evaluable patient who did not achieve TI12 has been transfusion free for 14.8 months. Iron removal therapy has been stopped for more than 6 months in 39/56 (69.6%) treated patients following infusion with CASGEVY, with sustained improvement in ferritin and liver iron content, suggesting that CASGEVY has the potential to correct ineffective erythropoiesis. Patients continue to demonstrate stable levels of fetal hemoglobin (HbF) and allelic editing. The safety profile of CASGEVY continues to be generally consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. Progress in bringing CASGEVY to patients Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales. In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending. Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or "sickled" red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Pr CASGEVY ® (exagamglogene autotemcel) Pr CASGEVY ® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Media: [email protected] orCanada: +1 647-790-1600orU.S.: 617-341-6992 SOURCE Vertex Pharmaceuticals (Canada) Inc.
Cision Canada
a day ago
- Cision Canada
Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada Français
Pluvicto ® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as more jurisdictions recognize radioligand as a critical therapy for advanced prostate cancer MONTREAL, July 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This new funding milestone marks a significant expansion in access to this innovative radioligand therapy. With reimbursement now secured in Quebec, Pluvicto ® is publicly funded in the country's four most populous provinces, bringing new treatment opportunities to Canadians living with PSMA-positive mCRPC who have previously undergone androgen receptor pathway inhibition and taxane-based chemotherapy. "We have been looking forward to this day for some time now as it represents a significant breakthrough for people in Quebec who have been longing for access to this much-needed treatment," said Laurent Proulx, President and CEO of PROCURE. "This progress brings real hope to countless patients and highlights how vital it is to make cutting-edge therapies available across Canada. We urge all provinces to keep moving forward so that every eligible patient, no matter where they live, can benefit from the best possible care and quality of life." Reimbursement in Quebec gives physicians more flexibility to integrate radioligand therapy into the treatment path for appropriate patients with advanced disease. "Public reimbursement of Pluvicto ® in Quebec is a meaningful advancement for individuals with PSMA-positive mCRPC who have already undergone multiple lines of treatment," said Dr. Frédéric Arsenault, President, Association des médecins spécialistes en médecine nucléaire du Québec. "Expanding access to radioligand therapy, a growing pillar in cancer care, marks a shift toward a new era of precision treatment that reflects the rapidly advancing oncology landscape. This decision helps close a longstanding treatment gap and will allow patients to receive timely treatment and care that offers hope and the potential to improve quality of life 1." Pluvicto ® is now publicly reimbursed in seven provinces: Quebec, Ontario, Alberta, British Columbia, Nova Scotia, Saskatchewan, and Newfoundland and Labrador. Each provincial listing extends access to more patients across the country and signals growing recognition of radioligand therapy as an important addition to advanced prostate cancer treatment options. "This announcement adds to the growing momentum behind the adoption of Pluvicto ® and radioligand therapy in prostate cancer care," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "It sends a strong signal that this approach is being recognized as a key part of the evolving cancer treatment landscape. We'll continue working closely with other jurisdictions to maintain this progress and help ensure every eligible patient across the country can access this important treatment option." Approved by Health Canada in August 2022, Pluvicto ® is the first targeted radioligand therapy for the treatment of PSMA-positive mCRPC in Canada 2. About Pluvicto ® Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy 2. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) 2. After administration into the bloodstream, Pluvicto ® binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein 2. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death 2. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit Pluvicto is a registered trademark. SOURCE Novartis Pharmaceuticals Canada Inc.
Cision Canada
a day ago
- Cision Canada
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England , July 3, 2025 /CNW/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark, confirming compliance with European safety and performance standards. This important milestone expands access to hip resurfacing, enabling wider availability across the UK, Europe and internationally where CE marking supports market access. "This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material," said Mike Tuke, Founder of MatOrtho. "That became a possibility with BIOLOX® delta and cooperation with CeramTec A.G. which led in stages to ReCerf – an all-ceramic resurfacing implant that is already delivering excellent results. We're proud to make this more widely available to specialist hip resurfacing surgeons, and patients who want to stay active." ReCerf is the world's first commercially available ceramic HRA, first approved by Australia's Therapeutic Goods Administration in November 2024. Since its initial use in 2018, over 1,600 patients have received the device. Patient-reported outcomes are highly positive, and the revision rate remains very low up to six years. Made from BIOLOX® delta ceramic, ReCerf eliminates concerns historically associated with metal-on-metal bearings and preserves more of the patient's natural bone. For surgeons, it offers a familiar procedure underpinned by improved materials, and is supported by a company long recognised as the home of modern hip resurfacing. ReCerf's availability under CE marking is matched by a strong commitment to responsible adoption. MatOrtho supports structured education, careful patient selection, and ongoing clinical monitoring. A peer-led surgeon training programme is already in place to ensure safe and effective use. This achievement strengthens MatOrtho's strategic growth and reaffirms its leadership in pioneering orthopaedic solutions designed to restore normal joint function and support high level activity. MatOrtho (formerly Finsbury Orthopaedics) is a global leader in orthopaedic invention and innovation, committed to advancing joint replacement technologies that improve patient outcomes and set new clinical standards.
